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Abstract 
R-spondin3 (RSPO3) is a member of a family of secreted proteins that enhance Wnt signaling pathways in diverse 
processes including cancer. However, the role of RSPO3 in mammary gland and breast cancer development 
remains unclear. In this study, we show that RSPO3 is expressed in the basal stem cell-enriched compartment of 
normal mouse mammary glands but is absent from committed mature luminal cells in which exogenous RSPO3 
impairs lactogenic differentiation. RSPO3 knockdown in basal-like mouse mammary tumor cells reduced canonical 
Wnt signaling, epithelial-to-mesenchymal transition-like features, migration capacity, and tumor formation in vivo. 
Conversely, RSPO3 overexpression, which was associated with some LGR and RUNX factors, highly correlated 
with the basal-like subtype among breast cancer patients. Thus we identified RSPO3 as a novel key modulator of 
breast cancer development and a potential target for treatment of basal-like breast cancers. 
 
Introduction 
R-spondins (roof plate-specific spondins; RSPOs) represent a group of four secreted proteins (RSPO1–4) that 
have been described in vertebrates. All four RSPOs have similar domain structures with two amino-terminal furin-
like repeats and a thrombospondin domain situated towards the basic amino acid-rich carboxyl terminal domain 
which can bind matrix glycosaminoglycans and/or proteoglycans [1]. RSPOs potently enhance both canonical, 
through β-catenin activation, and non-canonical Wnt signaling pathways [2-4]. At the cell membrane, secreted 
RSPOs simultaneously bind to leucine-rich repeat-containing G-protein coupled receptors 4, 5 or 6 (LGR4-6) [5, 
6], and to extracellular domains of two membrane-bound E3 ubiquitin ligases, Zinc and RING finger 3/RING finger 
43 (ZNRF3/RNF43). This ternary complex, LGR-RSPO-ZNRF3/RNF43, induces auto-ubiquitination and 
membrane clearance of ZNRF3/RNF43, allowing the WNT receptor, Frizzled (FZD), to accumulate and enhance 
the activation of Wnt pathways [7].  
WNT ligands activate canonical Wnt signaling by binding to FZD receptor, inducing the release of β-catenin from a 
cytosolic destruction multi-protein complex and its translocation to the nucleus where it acts as a co-activator of 
the TCF/LEF family of transcription factors, promoting target gene transcription. This signaling pathway is 
essential to several developmental processes by regulation of cell proliferation, differentiation, and migration, 
whilst its de-regulation underlies a wide range of pathologies including cancer [8].   
The mammary gland undergoes most of its development postnatally, progressing through a series of 
developmental cycles regulated by systemic hormones and local factors [9, 10]. The mammary epithelium is 
composed by luminal and basal compartments, surrounded by adipocytes and other stromal cells. The basal 
compartment consists of myoepithelial cells with contractile capacity and WNT-responsive mammary stem cells 
(MaSCs) [11] that reconstitute the gland upon transplantation into cleared mammary fat pads of host syngeneic 
mice [12]. Importantly, LGRs have been recently described as MaSC markers and are WNT-regulated target 
genes [13, 14]. Moreover, canonical Wnt signaling plays a critical role in controlling the enormous tissue 
expansion and remodeling during mammary gland development [15] through the maintenance and differentiation 
of MaSCs [16], and is implicated in breast carcinogenesis [17].  
Due to their Wnt pathway-potentiating activity, RSPOs play critical roles in embryonic development and 
organogenesis as well as in the self-renewal and maintenance of stem cells in some adult tissues [1]. Likewise, 
genomic rearrangements and transcriptional activation that result in elevated RSPO expression have been 
recently identified in mouse and human tumors, suggesting RSPOs may be functionally relevant for tumor 
development [18-20]. Particularly, RSPO3 promotes angio- and vasculogenesis [21, 22], several steps during 
embryogenesis [4], and represents a potent intestinal stem cell factor [23]. Acting through canonical and non-
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canonical Wnt pathway activation, RSPO3 has been recently implicated in several cancer models including 
colorectal, ovarian, and lung cancer [24, 25].  
Several years ago, mouse mammary tumor virus (MMTV) insertions that promoted Rspo3 overexpression were 
identified [26, 27]. However, the role of RSPO3 in breast cancer and normal mammary gland development 
remains unclear. Here, we show that RSPO3 is expressed in the basal stem cell-enriched compartment of the 
mouse mammary gland. In mammary tumor cells its overexpression is associated with the maintenance of 
mesenchymal-like features, migration capacity and in vivo tumorigenesis. Moreover, we found that RSPO3 is 
associated with the basal-like human breast cancer subtype, which lacks efficient therapeutic options.  
 
Materials and methods 
Cell culture, transfections, and differentiation procedures 
The following mouse mammary cell lines, obtained directly from their originating laboratories or from American 
Type Culture Collection (ATCC), were used in this study: HC11 and EpH4 (Dr. Bernd Groner; Georg-Speyer-
Haus), LM3 (Dr. Elisa Bal; Institute of Oncology Ángel H. Roffo), NMuMG (ATCC), SCg6 and SCp2 (Dr. Mina 
Bissell; Lawrence Berkeley National Laboratory), and LM38-LP (Dr. Laura Todaro; Institute of Oncology Ángel H. 
Roffo) [28]. Since no mouse STR DNA fingerprinting analysis is available for them to date, no authentication was 
performed (see Supplementary Material for culture and differentiation procedures). SCg6 cells were stably 
transfected with pGIPZ/tGFP/shScrambled/Puromycin or with different shRNA sequences of 
pGIPZ/tGFP/shRSPO3/Puromycin (Thermo-Scientific), and resistant clones were selected with 2 µg/ml puromycin 
(Sigma-Aldrich) for 4 weeks. For epithelial-to-mesenchymal transition (EMT) assay, NMuMG cells were incubated 
with 60 ng/ml recombinant RSPO3 protein (rRSPO3; R&D) or 2 ng/ml TGFβ (Sigma-Aldrich) at indicated times. All 
cell lines used in this study were maintained in culture for 4 to 5 weeks, regularly monitored for mycoplasma 
contamination by PCR using specific primers and discarded in case of positive results.  
RT-qPCR 
Total RNA was isolated using TriReagent (MRC) according to the manufacturer’s instructions. For RT, 250 ng or 1 
µg RNA from sorted mouse mammary cell populations or cell cultures, respectively, were used. All qPCRs were 
performed using SYBR Green (Roche) and Stratagene Mx3000P System (Agilent-Technologies). Gene 
expression levels were normalized to Actinb1, Gapdh or Hsp90ab1 as reference genes using standard curve 
method. See Supplementary Material for more details and primer sequences. 
Protein analysis 
Total proteins were extracted in RIPA buffer and used for Western blotting (WB). Blocked membranes were 
incubated with primary and secondary antibodies as follows: pAKT and AKT (Cell-Signaling; 4060S and 9272, 
respectively), E-cadherin (Thermo-Scientific; 13-1900; ECCD2 clone), p-JNK, JNK, β-Actin and GAPDH (SCBT; 
sc-6254, sc-474, sc-1616 and sc-20357, respectively), RSPO3 (R&D Systems; MAB41201), Vimentin (Abcam; 
7783-500), IgG anti-mouse, anti-rabbit, or anti-rat (SCBT; sc-2005, sc-2004, and sc-2032, respectively). More 
details in Supplementary Material.  
Conditioned media  
To obtain conditioned media (CM), cells were cultured in supplemented medium for 24 h that was replaced with 
serum-free medium for another 24 h or 48 h, as indicated. CMs were collected, precipitated overnight at -20°C 
with acetone, and centrifuged at 1500g and 4°C for 20 min. Pellets were resuspended in 40 µl PBS containing 
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SDS sample buffer and used for WB. For competitive assay, cells were incubated with increasing concentrations 
of KClO3 (Sigma-Aldrich) in serum-free medium prior CM collection.  
Wound healing assay 
Confluent monolayers were wounded with a pipette tip, cell debris was removed by washing with warm medium 
and cells were cultured for 15 h in serum-free medium. Images were captured using an Olympus SP-350 digital 
camera mounted on a microscope after wounding (t=0h) and 15 h later. Analysis was performed using Image-Pro-
Plus software and wound sizes in experimental monolayers were expressed relatively to controls. 
β-catenin transcriptional activity 
Cells were transfected with 1 µg/well of pGL3-OT (TOP-Flash-like, TCF-LEF/β-catenin reporter), and pCMVLacZ 
as a control. Transfections were performed using Polyethylenimine (Polysciences) according to manufacturer’s 
instructions. Cell extracts were prepared 48 h or 72 h later, using Reporter Lysis Buffer (Promega). Luciferase 
pGL3-OT activity was normalized to pCMVLacZ β-galactosidase activity. See Supplementary Material for detailed 
data. 
Immunofluorescence 
Fixed cells or 5-µm paraffin sections of mammary glands from 12-week-old mice were incubated with F-actin 
probe Rhodamine Phalloidin (Sigma-Aldrich), anti-αSMA (Abcam, ab21027), anti-β-catenin (BD; #610154), anti-
ERα (SCBT; sc-542), anti-Fibronectin (Sigma; F6140; clone FN-3E2), anti-RSPO3 (Sigma-Aldrich; HPA029957) or 
anti-Vimentin (Abcam; 7783-500) antibodies followed by incubation with Alexa Fluor 555 goat anti–mouse IgG, 
647 donkey anti–mouse IgG, 488 donkey anti-goat IgG, and 647 donkey anti–rabbit IgG (Life-Technologies). Cells 
were also stained with DAPI (Roche). Slides were examined under an Olympus FV100 confocal microscope and 
images were analyzed with MacBiophotonics ImageJ. See Supplementary Material for more details. 
Animals 
Virgin female mice from C57BL/6 and BALB/c strains were maintained in a specific pathogen–free facility at the 
FCEN-UBA-CONICET, at constant temperature and humidity with a 12 h light cycle. Animals were allowed food 
and water ad libitum. Mouse experiments were approved by local IACUC authorities and complied with regulatory 
standards of animal ethics.  
Cell isolation and fluorescence-activated cell sorting 
Lymph node-free mammary glands from 12-week-old virgin C57BL/6 mice were minced and digested to obtain 
single-cell suspensions prior flow cytometry analysis. See Supplementary Material for more details. For FACS, 
5×10
5
 cells from mouse single-cell suspensions were stained with fluorophore-conjugated antibodies (BioLegend). 
Specifically, cells were stained with anti-mouse CD31/CD140a/TER119/CD45-PE (Lineage cocktail; clones 145-
2C11, RB6-8C5, M1/70, RA3-6B2 and Ter-119), anti-hamster IgG/anti-rat IgG2b/anti-rat IgG2a as lineage cocktail 
isotype controls, anti-mouse CD24-APC (clone M1/69) or anti-mouse CD29-FITC, for 30 min on ice in 10% (v/v) 
FBS/PBS. Stained populations were analyzed and sorted on a BD FACS Aria (II) Cell Sorting System (BD). Data 
acquisition and analysis were performed using FACS Diva software (BD). 
In vivo studies 
Six-week-old virgin BALB/c female mice were injected subcutaneously into the right ventral flank or within the right 
4
th
 mammary fat pad with 4×10
5
 SCg6-shRspo3 or SCg6-shControl cells in 100 µl DMEM-F12 (8 mice per group; 
n=3). Alternatively, 20-day-old BALB/c female mice were subjected to standard mammary fat pad clearing and 
then injected with the same amount of the indicated cells within the #4 cleared fat pads. Tumor measurements 
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were carried out blindly with a caliper twice per week, and volumes were calculated using the formula 
V=π/6×length×(width)
2
. Mice were euthanized when they met the institutional criteria for tumor size and overall 
health condition. Tumors were fixed in PBS-buffered 4% (v/v) formalin solution and embedded in paraffin. Lung 
experimental metastasis was induced by injecting 7×10
5
 cells in 100 μl PBS through the tail vein. Up to 4 weeks 
post-injection, animals were euthanized and their lungs were fixed via tracheal instillation of 4% (v/v) buffered 
formalin prior to removal. Paraffin-embedded lung samples were stained with H&E and entirely scanned. 
Metastatic regions in H&E-stained lungs were quantified by a metastasis area index, calculated as the ratio of 
metastasis to total lung areas. 
Immunohistochemistry 
Immunohistochemistry (IHC) analysis were performed on 5-µm paraffin sections either of mammary glands from 
12-week-old mice, mouse tumors and lungs samples, or human mammary tissues with the Vectastain Elite ABC 
HRP Kit (Vector-Laboratories) according to the manufacturer’s instructions. Primary antibodies used were as 
follows: αSMA (Thermo-Fisher-Scientific, #RB-9010), cleaved-caspase3 (CC3) (Cell-Signaling; 9661), ERα 
(SCBT; sc-542), Ki67 (Abcam; ab15580), KRT-14 (Thermo-Fisher-Scientific; #RB-9020), RSPO3 (Sigma-Aldrich; 
HPA029957), SOX2 (Cell-Signaling; 3728) or Vimentin (Abcam; 7783-500). For CC3 and Ki67 quantification, cells 
were counted at 1000X (5 fields per section at least; 1000 cells per field) excluding boundaries and necrotic 
regions; n=3.  
Human mammary tissues 
Tissue microarray (TMA) of breast cancers was purchased from US Biomax (#BR1505b). Paraffin-embedded 
breast tissue specimens were acquired from hospitals associated to the School of Medical Sciences - National 
University of La Plata, after obtaining written informed consents from patients (according to Declaration of 
Helsinki, 2000) and the approval by the Institutional Review Board.  
In silico analysis 
Comparative analysis of RSPO3, CDH1, FN1, VIM, SNAI1, SNAI2 and TWIST gene expression was performed in 
51 breast normal and cancer cell lines obtained from three independent studies (GSE10843, GSE12777 and 
GSE41445). Expression profiles were developed using the Affymetrix HG-U133 Plus2 platform (GPL570). Mouse 
Rspo3 mRNA expression was analyzed among luminal cells isolated from the mammary glands of adult female 
mice derived from the GSE47377 dataset obtained from GEO2R resource. Visualization and statistical analysis of 
RSPO3 expression were done with R/Bioconductor. Comparative analysis of RSPO3, LGR4-6, RUNX1-3 mRNA 
expression profiles across 1097 primary human breast carcinomas was performed using The Cancer Genome 
Atlas (TCGA) Network, breast cancer project. Correlation analysis was done with Pearson's test using corrplot R 
package. Profiles were also compared according to PAM50-intrinsic subtypes and ESTIMATE (Estimation of 
STromal and Immune cells in Malignant Tumors using Expression data) scores. Comparative analysis of RSPO3, 
ER/PR/HER2 and CDH1/VIM/SNAI2/TWIST mRNA expression among 1985 breast cancer samples was done 
using the METABRIC dataset. Kruskal-Wallis and Chi-squared were used as statistic tests. See Supplementary 
Material for more details. 
Statistical methods 
Statistical significance of differences was evaluated using the software GraphPad Prism5 (La Jolla, CA, USA). 
Data are presented as mean ± s.e.m unless otherwise noted.  
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Results 
RSPO3 is expressed in distinct mouse and human mammary cell lines 
In order to assess whether Rspo3 is expressed in mammary cells in the absence of MMTV infection, we 
performed an in silico RSPO3 mRNA profiling analysis in a set of 51 human breast normal and cancer cell lines. 
Obtained values revealed that breast cancer cells express high levels of RSPO3 as compared to the non-
tumorigenic cell line MCF-10A. Interestingly, among tumor cells, RSPO3 mRNA levels resulted higher in basal-like 
(ER
-
PR
-
) than in luminal-like (ER
+
PR
+
) breast cancer cell lines (BCCLs). Notably, a subset of basal ER
-
PR
-
 cells 
(i.e., MDA-MB-436, HCC1143, BT549, HDQP1, and Hs578t), which are characterized by low expression of 
epithelial cell-cell adhesion and luminal differentiation markers, as well as by high expression of genes involved in 
EMT and cancer stem cell (CSC) features
 
[29], showed the highest level of RSPO3 expression (Figure 1A, 1B and 
S1). Besides, we determined a significant correlation of RSPO3 with some of those markers, as CDH1, VIM and 
TWIST1 (Figure 1C and D). In addition, analysis of mouse mammary tumors also revealed that ER
- 
cells (LM38-
LP and SCg6) express higher levels of Rspo3 than ER
+
 tumor cells (C4 derived, MPA-induced tumors, see 
Supplementary Material) (Figure 1E). Among non-tumor cell lines (HC11, EpH4 and SCp2), we found that Rspo3 
mRNA levels were associated with vimentin expression, a broadly used basal/mesenchymal marker, and that 
proliferating HC11 cells showed the highest Rspo3 levels (Figure 1E). This cell line produces its own extracellular 
matrix and resembles mammary stem/progenitor cells in the proliferating undifferentiated stage, exhibiting 
pluripotent capacity and expression of proteins associated to mesenchymal phenotype [30]. Importantly, as these 
cells reached lactogenic differentiation, Rspo3 expression significantly decreased, similarly to vimentin levels 
(Figure 1E). 
At the protein level, it was determined that RSPO3 is secreted to the extracellular space, as it was detected in the 
CM of cultured mammary tumor cells (Figure 1F). Our results also confirmed that, once secreted, RSPO3 may 
strongly interact with membrane-associated and/or extracellular matrix heparan sulfate proteoglycans, since the 
addition of potassium chlorate, an inhibitor of sulfation, increased RSPO3 levels in the CM of mammary tumor 
cells (Figure 1G).  
RSPO3 is differentially expressed in stromal and basal mammary subpopulations 
To determine whether RSPO3 is constitutively expressed in the normal mouse mammary gland, studies using IHC 
were carried out. RSPO3 cytoplasmic staining was detected in a subset of basal epithelial cells and within the 
stroma. Figure 2A shows its localization as well as the distribution of basal myo-epithelial markers cytokeratin 14 
(KRT14) and α-smooth-muscle actin (α-SMA), and the MaSC marker SOX2 [14] on serial mammary sections. 
Noteworthy, RSPO3 localization was clearly different from the luminal marker, estrogen receptor-α (ERα) (Figure 
2A and B) and co-immunofluorescent studies also revealed accumulation of RSPO3 surrounding α-SMA positive 
cells (Figure 2B).  
To identify the specific subpopulations expressing Rspo3, we examined its mRNA level in FACS-purified luminal 
(Lin
-
CD24
hi
CD29
+
), MaSC-enriched basal (Lin
-
CD24
+
CD29
hi
) epithelial and stromal (Lin
-
CD24
-
CD29
+
) populations 
(Figure 2C). The successful separation was confirmed by Krt18 (luminal), Krt14 (basal) and Vim (basal/stromal) 
marker expression analysis (Figure 2D). We found that Rspo3 was predominantly expressed in stromal cells and 
in the MaSC-enriched basal epithelial fraction. Interestingly, in the mammary epithelial compartment, we observed 
that Rspo3 levels displayed a similar distribution as its putative receptor, the basal MaSC marker, Lgr4 [14] 
(Figure 2D). Collectively, these data demonstrate that RSPO3 is expressed in normal mammary glands of adult 
virgin female mice both in the stem cell-enriched basal epithelial and stromal populations, whereas it is absent 
from committed luminal epithelial cells. 
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RSPO3 is associated with basal phenotype in mammary cells 
As indicated above (Fig. 1E), Rspo3 levels decrease as HC11 cells reach lactogenic differentiation in culture. In 
addition, in silico analysis revealed that the committed alveolar luminal cell population of mid-pregnant animals 
expresses lower levels of Rspo3 than alveolar luminal stem/progenitor mammary cells of virgin mice (Figure 3A). 
Moreover, we determined that recombinant RSPO3 (rRSPO3) protein significantly reduced β-casein expression 
levels in luminal-like, functionally normal SCp2 and EpH4 cells under lactogenic conditions (Figure 3B). To further 
investigate whether RSPO3 could alter mammary epithelial phenotype, we cultured NMuMG cells with rRSPO3 
protein. It was observed that rRSPO3 induced canonical Wnt pathway activation (Figure S2A) and promoted the 
acquisition of fibroblast-like, mesenchymal morphology, similar to that obtained with transforming growth factor-β 
(TGF-β) (Figure 3C). We detected a significantly increased expression of the mesenchymal markers fibronectin 
and vimentin, and a reduced expression of the epithelial marker E-cadherin by RT-qPCR and/or WB analysis 
(Figure 3D and E). Similar results were obtained in SCp2 cells after rRSPO3 treatment (Figure S2B). Taken 
together, these results suggest that RSPO3 could play a relevant role in the normal mammary gland biology, 
promoting the maintenance of an uncommitted basal-like mammary epithelial phenotype and inducing EMT-like 
and CSC features, which may be the underlying mechanisms for transforming breast cancer cells that 
overexpress RSPO3.  
To validate the involvement of RSPO3 in the malignant phenotype of basal cancer cells, the SCg6 cell line, which 
expresses high levels of Rspo3 (Fig. 1E), was stably transfected with a scrambled shRNA (shControl) or with four 
different Rspo3 shRNA sequences. Two clones (#2A and #4B) displaying a knock-down (KD) efficiency of ~50% 
at mRNA and protein levels were selected for further studies (Figures 4A and S3A). Rspo3-KD cells showed a 
change in cell morphology from spread-out, mesenchymal-like to cobble-stone, epithelial-like cells when cultured 
up to confluence (Figure 4B). Although subtler, cell shape differences were also detected at sub-confluence 
(Figure S3B). Consistently, F-actin was predominantly reorganized into cortical bundles associated with cell-cell 
adhesions in Rspo3-KD cells in contrast to the F-actin assembled into thick parallel bundles, or actin stress fibers, 
in shControl cells (Figure 4C). Moreover, an increase in membrane-bound β-catenin levels, as a key component of 
cell–cell adhesion, was obtained in Rspo3-KD cells as compared to stabilized-cytoplasmic β-catenin displayed by 
shControl cells (Figure 4D). Although E-cadherin expression remained undetectable, analysis of 
basal/mesenchymal markers revealed a reduction of vimentin and fibronectin levels in Rspo3-KD cells, as 
compared to shControl cells (Figure 4E and F). We also determined that the morphological change observed in 
Rspo3-KD cells was accompanied by a significant decrease in migration capacity (Figure 4G).  
Then, we investigated the signaling pathway underlying RSPO3 activity in tumor basal mammary cells. While no 
changes in JNK phosphorylation levels were found (Figure S3C), as a non-canonical Wnt pathway activation 
marker, Rspo3-KD cells displayed a significant reduction of canonical Wnt pathway activation, since less nuclear 
β-catenin activity was detected by reporter gene expression (Figure 4H). In addition, Rspo3-KD cells exhibited a 
reduction in AKT phosphorylation levels (Figure S3D), in agreement with several reports showing the role of 
phosphoinositide 3-kinase (PI3K)/AKT pathway in enhancing canonical Wnt pathway during normal mammary 
gland development and tumorigenesis [31]. Taken together, these results suggest that RSPO3 could be relevant 
for breast cancer progression favoring the maintenance of a migratory basal/mesenchymal-like phenotype 
possibly through canonical Wnt pathway activation and a crosstalk with the PI3K/AKT cascade.  
Rspo3-KD reduces in vivo tumor growth and metastasis in basal mammary cancer cells 
To determine the effect of knocking-down Rspo3 on tumor growth in vivo, Rspo3-KD and shControl SCg6 cells 
were subcutaneously injected into female mice. It was determined that shControl-derived tumors appeared earlier 
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and grew faster than those obtained from Rspo3-KD cells. Nine days after cell injection all shControl-derived 
tumors were palpable and had to be euthanized 20 days after injection due to their tumor size. In contrast, tumors 
from Rspo3-KD cells appeared much later, or did not show tumor development even after 60 days post-inoculation 
(Figure 5A). A similar study was performed inoculating parental, shControl and Rspo3-KD SCg6 cells into the #4 
mammary fat pads, up to 20 days post-injection to compare tumors at the same end-point. Once again, tumors 
from Rspo3-KD cells arose later and were smaller than those derived from control cells (Figures 5B and C). 
Histological analysis revealed that both Rspo3-KD and shControl tumors expressed RSPO3 and were composed 
by undifferentiated spindle cells that invaded mammary fat tissue and entrapped host mammary ducts (Figure S4). 
In addition, when Rspo3-KD and shControl cells were transplanted into cleared fat pads, no differences to the 
previous approaches regarding tumor growth were detected. After 9 days shControl tumors reached 69.9±23.3 
mm
3
 and displayed invasive behavior towards the fatty stroma, while Rspo3-KD-derived tumors were barely 
palpable and looked encapsulated (H&E staining, Figure 5D). Besides, Rspo3-KD implants displayed 
heterogeneous lower expression of RSPO3 and Vimentin, as well as less Ki67 positive nuclei and a higher 
number of Cleaved-Caspase3 (CC3) positive cells, compared to shControl tumors (Figure 5D).  
To determine whether RSPO3 also affects secondary tissue invasion, Rspo3-KD and shControl cells were injected 
into the tail vein of female mice. Fifteen days after injection, mice carrying shControl cells exhibited lung micro-
metastasis, which fully developed into macro-metastasis that comprised the entire lungs two weeks later. In 
contrast, no tumor tissue was observed in lungs of mice carrying Rspo3-KD cells 15 days post-inoculum, and in 
only one of them a single macro-metastasis was found 30 days after injection (Figure 5E). Besides, sequentially 
sliced lungs of mice inoculated with Rspo3-KD cells showed a significant reduction in the number of micro-
metastasis compared to controls (Figure 5F and G). All together, these data demonstrate the relevance of RSPO3 
for in vivo development of a basal mammary tumor model. 
RSPO3 is overexpressed in human breast cancer and is associated with basal-like tumors 
In order to assess RSPO3 expression in human mammary tissue, IHC was performed on 21 samples of malignant 
and benign breast lesions. We found that most of these samples showed positive immunoreactivity for RSPO3 
(62%; 13/21) (Figures 6 A-D and Table S1). Furthermore, RSPO3 was clearly detected in the basal compartment 
of differentiated ducts and lobules in neoplastic and non-neoplastic samples (Figures 6 E-H). RSPO3 expression 
was then analyzed by IHC in a TMA of 74 invasive ductal breast carcinoma cases. Notably, 70% (52/74) of tumors 
showed low to strong RSPO3 positive staining, while only 30% (22/74) resulted negative (z-test: p<0.001; Figure 
6I-N). When RSPO3‐score was compared with clinical and histopathological parameters, neither clinical stage nor 
biomarker (ER/PR/Her2 and Ki67) expression exhibited a significant correlation with RSPO3 levels (Tables S2-4). 
However, the expression data of the TCGA-Breast cancer project from 1985 human breast carcinomas, revealed 
that RSPO3 was highly expressed in triple-negative (TN) samples (ER
-
PR
-
Her2
-
) compared to ER
+
 subtypes 
(ER
+
PR
+/-
Her2
+/-
) (Figure 7A), and showed significant RSPO3 overexpression in the basal-like subtype (Figure 
7B). Moreover, by sub-dividing basal-like breast cancer category within the intrinsic subtypes, we determined 
significantly high RSPO3 expression in claudin-low, basal-like tumors (Figure 7C), which are characterized by low 
to absent expression of differentiated luminal cell markers, high enrichment for EMT markers, immune response 
genes, and CSC-like features [29]. Besides, RSPO3 mRNA levels were negatively correlated with epithelial 
markers, as E-cadherin, and positively with the EMT and CSC markers, vimentin, SLUG and TWIST, in primary 
human breast tumors (Figure 7D). Then, through the ESTIMATE method, we found that RSPO3 expression was 
associated with elevated lymphocytic and stromal components (Figure 7E), which are present in most basal-like 
breast cancers [32]. Nevertheless, no significant association between RSPO3 mRNA expression and lower overall 
survival was detected in patients with basal-like primary breast carcinomas (Figure S5A). 
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Finally, to propose RSPO3 as a relevant autocrine breast tumor factor, we analyze expression levels of certain 
factors previously shown to promote RSPOs expression and activity. In silico analysis revealed that among breast 
carcinomas RSPO3 is expressed in association with the three RSPOs receptors, LGR4-6 (Figure 7F), and showed 
a positive correlation with the runt-related transcription factor (RUNX) family (Figure S5B) that may induce Rspo3 
expression in mammary tumor cells [33]. Particularly, RSPO3 levels significantly correlated with LGR4-6 and 
RUNX3 levels, among the members of these two families (Figure 7G). Comparisons between different intrinsic 
molecular breast cancer subtypes revealed that these genes were also overexpressed in the basal-like subtype 
(Figure 7H), consistently with RSPO3 expression.   
 
Discussion 
Activation of Wnt pathway has been described as a cell-biological program required for the correct development of 
the mammary gland [15], particularly promoting the maintenance and differentiation of MaSCs [16]. RSPOs and 
LGR4–6 were recently found to constitute a ligand-receptor system with critical roles in normal development and 
stem cell survival through modulation of Wnt signaling in several tissues [5, 6]. However, their roles in breast 
carcinogenesis have been less explored. Previously, we identified MMTV-promoted Rspo3 up-regulation [26], 
which led to mammary tumor formation in mice [27]. We have also observed that 3T3 cells overexpressing Rspo3 
showed cell contact inhibition and anchorage-independent growth, which confirmed its pro-oncogenic capacity, as 
well as modulation of AKT and JNK signaling pathways (Figure S6, A-D).  
Here, we show that RSPO3 is overexpressed in human BCCLs compared to non-tumor cells. Interestingly, the 
highest levels of RSPO3 mRNA were found in a subset of basal-like BCCLs with a highly aggressive phenotype 
and EMT and CSC features [34]. Consistently, established basal-like mouse mammary cell lines that exhibited 
high Rspo3 levels also expressed vimentin, a basal/mesenchymal marker described as a target of canonical Wnt 
pathway activation promoting cell migration and invasion in human breast cells [35]. The association between 
Rspo3 and vimentin was also evident in the non-tumorigenic mammary cell line HC11, since detectable levels of 
both mRNAs were found in the proliferative phase. Interestingly, proliferative-undifferentiated HC11 cells are 
considered stem-like cells due to their self-renewal and pluripotent capacity [30]. In agreement with these 
observations, we determined that in mice Rspo3 is expressed by the basal, stem cell-enriched mouse mammary 
compartment, associated with the expression of the RSPOs’ receptor, Lgr4. Likewise, RSPO3 was detected in the 
basal layer of neoplastic and non-neoplastic ducts in human glands. Thus, these findings suggest that RSPO3 
might be playing a relevant role in Wnt pathway activation and MaSCs maintenance. A similar role of RSPO3 has 
been described in the intestinal stem niche, where it enhances the activity of WNT ligands secreted by epithelial 
and stromal populations [23]. In fact, inhibition of RSPO3 activity, using blocking antibodies in human colorectal 
tumor xenographs, reduces the expression of several tumor stem cell-associated genes, thereby linking the 
activity of RSPO3 to the maintenance of epithelial homeostasis and the tumorigenesis of that tissue through 
hyperactivation of stem cell genes [25]. In addition, we showed that RSPO3, once secreted, remains bound to the 
extracellular matrix and/or face of the cell membrane, and therefore it may exert its activity on the same cell 
population. Moreover, we found that Rspo3 expression decreased as HC11 cells reach lactogenic differentiation, 
whereas rRSPO3 reduced -casein expression in differentiated luminal cells. Hence, our results suggest that 
RSPO3 would participate in maintaining the stem niche of the normal mammary gland, inhibiting differentiation of 
the luminal compartment.  
We are not the first to find out that a member of the RSPO protein family is present in the normal mouse 
mammary gland. It has been demonstrated that Rspo1 is expressed by luminal cells and, together with WNT4, 
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mediates hormone action on mammary stem cell expansion [36]. We still do not know whether Rspo3 expression 
in the gland is regulated during development. However, its presence in stromal and basal mammary cells 
suggests that RSPO3 would contribute to the maintenance of the MaSCs and/or the MaSC niche in the adult 
female mice, since it has been shown a similar distribution and biological role in the intestine [23]. Moreover, as 
RSPO1 mRNA levels resulted lower than RSPO3 in basal-like breast cancers (Figure 7B and S7), we propose 
that RSPO3 would play a more significant role in the development of this breast cancer subtype.  
Many extracellular factors and signaling pathways described in normal mammary gland development and 
tumorigenesis, such as the canonical Wnt pathway, are also involved in the process of EMT [37-39]. In this study, 
we observed that RSPO3 caused the acquisition of a spindle-shaped phenotype, typical of cells that have lost 
their epithelial properties, together with the modulation of relevant EMT markers. Interestingly, it has been 
determined that certain features associated with a partial EMT are visible in non-tumor conditions, playing an 
important role in adult tissue remodeling. For example, during normal mammary branching morphogenesis, EMT-
related genes are expressed specifically in terminal end buds, inhibiting epithelial differentiation in favor of the 
acquisition of migratory features [40, 41]. Therefore, the ability of RSPO3 to induce EMT-associated events might 
also be important for mammary gland development during puberty. 
Our results also demonstrate that RSPO3 is relevant for the migratory basal/mesenchymal-like phenotype in 
mouse mammary tumor cells, possibly through canonical Wnt pathway activation and a crosstalk with the 
PI3K/AKT cascade. This conclusion is based on the following obtained evidences: (1) RSPO3 promoted the 
maintenance of a spindle-shaped morphology and the expression of CSC- and EMT-associated genes such as 
vimentin and fibronectin; (2) RSPO3 increased the ability of basal tumor cells to migrate in culture and to grow and 
invade secondary tissues in vivo; (3) RSPO3 enhances canonical Wnt pathway activation and AKT 
phosphorylation, interplay also observed by our group in Rspo3-overexpressing 3T3 cells. Collectively, these 
results are consistent with reports showing that canonical Wnt signaling blockage decreases migratory potential 
and growth in soft-agar of basal-like breast cancer cells [42, 43] and that the crosstalk between β-catenin/Wnt and 
PI3K/AKT pathways plays a critical role in the regulation of normal and malignant stem/progenitor cells during 
mammary gland development and carcinogenesis [44, 45]. Besides, our in silico analysis shows that RSPO3 
mRNA levels were associated with high expression of stem cell markers in tumors from breast cancer patients. 
Therefore, RSPO3 might promote the transcription of stem cell-related genes during normal and neoplastic 
mammary development through activation of Wnt/AKT pathways. The long latency of shRspo3-SCg6 tumors 
indicates the relevance of this protein for in vivo tumor development. Since Claudin-low breast tumor cells show 
high expression of RSPO3, and this cancer subtype has been shown to be enriched in functional CSCs [46], we 
postulate that inhibiting expression of RSPO3 in SCg6 cells may decrease their cancer stem properties, reducing 
the capability of tumor grafting and growth in vivo. Therefore, the impact of altering RSPO3 levels on Wnt pathway 
activation, EMT and migration capacity observed in culture would be associated to SCg6-cancer stem cell 
population ability for survival, grafting and generation of the appropriate microenvironment for tumor implantation 
and development in vivo.  
By IHC, we found that most tumor samples from 74 breast cancer patients resulted positive for RSPO3, while no 
significant association between this protein and the levels of clinically relevant biomarkers was determined. 
However, RNA-Seq analysis of 1985 human breast carcinomas from the TCGA-Breast cancer database revealed 
that RSPO3 was highly expressed in TN samples, compared to ER
+
 tumors, independently from their PR and 
Her2 levels, and in the basal-like subtype among the intrinsic categories [29]. This cancer subtype is a 
heterogeneous breast cancer group with less therapeutic options than luminal tumors, since they lack ER/PR 
expression and Her2/Neu
+
 amplification. Several studies have recently demonstrated a high cytoplasmic and 
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nuclear accumulation of β-catenin in ~60% of human breast cancers, particularly in TNs, associated with the 
expression of EMT-related genes [47] and a MaSC enrichment [48-50]. These results, beyond relating canonical 
Wnt pathway with a poor clinical prognosis, showed that this activation was not due to mutations in β-catenin 
gene, highlighting the importance of studying new factors, as RSPO3, that could enhance canonical Wnt pathway 
activation in the most aggressive forms of breast cancer. Interestingly, we determined a positive association of 
RSPO3 with LGR4-6 and RUNX3, which are also over-represented in the basal subtype. Although a dual activity 
of RUNX genes in promoting or inhibiting breast cancer development has been established [51], the data shown 
herein are consistent with our recent report showing that RUNX1 activates the transcription of Rspo3 in mouse 
mammary tumor cells [33]. Therefore, we propose that deregulation of the RUNX family might also lead to RSPO3 
overexpression in human breast cancer. However, further studies will be required to dissect the exact mechanism 
of how the RUNX3-RSPO3-LGR axis functions to modulate Wnt signaling in TN breast cancers. 
Within the basal category, we found a significant higher expression of RSPO3 in the claudin-low subtype. It has 
been shown that in both mice and humans, this subtype has the largest percentage of tumors in which the MaSC 
signature predominates [52]. However, given that these aggressive tumors exhibit EMT and CSCs features [29], 
they may originate from the luminal progenitor population prior to acquiring adult MaSC and/or mesenchymal 
properties [52]. Therefore, we propose that in mouse and human mammary glands, RSPO3 is expressed in the 
progenitor population promoting their inherent stemness properties and preventing luminal differentiation. 
Eventually, RSPO3 overexpression in progenitor cells or expression in the luminal compartment might lead to 
malignant transformation and transdifferentiation through a process driven by EMT inducers. 
Finally, we suggest that RSPO3 might be a potential molecular target for the prevention and treatment of breast 
cancer, particularly the TN subtype. We hypothesize that blocking its activity might provide a new opportunity not 
only to reduce tumor bulk but also to deplete CSCs that initiate and promote metastatic spread and recurrence.  
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Figure legends 
Figure 1. RSPO3 is expressed in human and mouse mammary cancer cell lines. (A) RSPO3 mRNA 
expression profile based on a compiled in silico dataset of 50 human breast cancer cell lines (BCCLs): 27 luminal-
like and 23 basal-like BCCLs, and the non-tumorigenic MCF-10A cell line, obtained from GSE10843, GSE12777, 
and GSE41445 datasets. (B) Box plot of RSPO3 mRNA expression between non-tumor, luminal-like and basal-
like BCCLs from the compiled dataset, showing statistically significant differences between groups. (C) 
Hierarchical clustering analysis and (D) correlation matrix of RSPO3, CDH1, VIM, FN1, SNAI1, SNAI2, and 
TWIST among breast cancer cell lines using the same datasets as in A. Green squares in (D) show genes with 
statistically significant differences; p<0.01. (E) Reverse Transcription-quantitative PCR (RT-qPCR) analysis of 
Rspo3 mRNA expression levels and the basal/mesenchymal marker vimentin (Vim) in tumor (LM38-LP, SCg6, 
C4-L2, C4-HI, C4HD and C4-HIR) and non-tumor (HC11, SCp2 and EpH4) mouse mammary cells. Analysis of 
Rspo3 expression in HC11 cells was performed during proliferative stem-like (HC11-P) and lactogenic 
differentiation (HC11-D) stages. Expression data were normalized by HSP90ab1 mRNA and error bars are s.e.m. 
(n=3). (F) Representative Western blot (WB) analysis of RSPO3 levels in serum-free conditioned media (CM) and 
total cell lysates (TCLs) of indicated mouse mammary cell lines. LM3: ER
-
PR
-
 mouse mammary tumor cell line. 
Cells were cultured in serum-free medium for 24 or 48 h prior to harvesting. β-actin was used as a loading control. 
(G) Representative WB analysis of RSPO3 levels in TCL and serum-free CM of SCg6 cells incubated with 
increasing concentrations (0-25 mM) of potassium chlorate (KClO3), an inhibitor of sulfation. β-actin was used as a 
loading control. * high molecular weight band of RSPO3, possibly due to post-translational modifications. 
Figure 2. Rspo3 is expressed in the stroma and stem cell-enriched basal mammary epithelial cell 
subpopulations. (A) Immunohistochemical staining of serial mouse mammary sections with antibodies specific to 
RSPO3 and to stem (SOX2), basal (Cytokeratin14, KRT14, and α-SMA), and luminal (ERα) lineage markers. 
Lower panels correspond to higher magnification of upper images. Scale bars: 50 µm and 17 µm, respectively. (B) 
Representative micrographs of co-immunofluorescence assays showing RSPO3 (red), α-SMA (green, upper 
panels), and ERα (green, lower panels), in mouse mammary sections; DAPI (blue) shows nuclei. Scale bars: 50 
µm. (C) FACS segregation of lineage-negative (Lin: CD31, CD45, Ter119) mammary cells into luminal 
(CD24
hi
CD29
+
), stem cell-enriched basal (CD24
+
CD29
hi
) and stromal (CD24
-
CD29
+
) subpopulations. A 
representative FACS dot plot is shown. (D) RT-qPCR analysis of luminal Cytokeratin 18 (Krt18), basal Krt14, stem 
Lgr4, mesenchymal Vim markers, and Rspo3 expression in luminal, basal/stem and stromal FACS-sorted 
subpopulations normalized to HSP90ab1. Data represent mean +/- s.e.m. of three replicate experiments; Tukey´s 
test following one-way ANOVA. *, **, *** P<0.05; n.s. not-significant. All experiments were performed using 12-
week-old virgin female mice. 
Figure 3. RSPO3 inhibits lactogenic differentiation and promotes mesenchymal/basal phenotype in mouse 
mammary epithelial cells. (A) Rspo3 mRNA expression determined by oligo-microarray analysis (probe 
1443187_at) obtained from GSE47377 GEO Superserie of alveolar epithelial cells: luminal progenitors (LP) and 
luminal mature at mid-gestation (LM), isolated from the mammary glands of adult virgin female mice. (B) 
Quantitative expression analysis of β-casein gene. Mouse mammary luminal-like SCp2 and EpH4 cells were 
cultured in the presence of lactogenic hormones, with or without 1.5% v/v laminin-rich basement membrane 
(Matrigel) to promote lactogenic differentiation, and with or without rRSPO3 (60 ng/ml) for 72 h. Total RNA was 
isolated and subjected to RT-qPCR. (C) Representative micrographs showing morphological changes induced in 
NMuMG cells 24 h after treatment with rRSPO3 protein (60 ng/ml) or TGF-β (2 ng/ml) as an EMT-positive control. 
(D) RT-qPCR analysis of mesenchymal (vimentin and fibronectin) and epithelial (E-cadherin) markers in NMuMG 
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cells treated or not with rRSPO3 protein during 24 and 72 h. Gene expression data were normalized to HSP90ab1 
mRNA and is shown as fold change (mean +/- s.e.m.) relative to untreated cells. (E) Representative WB analysis 
of EMT-associated markers in NMuMG cells 24 h and 72 h after treatment with rRSPO3. β-actin was used as a 
loading control. Experiments B-E were performed in triplicate. Student´s t-test, *: P<0.05; n.s. not significant.   
Figure 4. Rspo3 down-regulation alters basal phenotype in tumor SCg6 mammary cells. (A) WB analysis of 
RSPO3 levels in SCg6 cells either naïve (Parental), or stably transfected with a scrambled shRNA (shControl) or 
with shRNA sequences targeting Rspo3 (shRspo3). 2A and 4B represent two different isolated clones. (B) 
Representative micrographs of confluent shRspo3-2A and 4B, and shControl cells. Original magnification: 200x. 
(C) and (D) Representative micrographs of immunocytochemistry assays showing F-actin (red) and β-catenin 
(red), respectively, in stably transfected shRspo3 (clone 4B) or shControl SCg6 cells; DAPI (blue) shows nuclei. 
Scale bars: 10 µm. (E) RT-qPCR analysis of basal/mesenchymal markers, vimentin and fibronectin, in shRspo3 
and shControl cells. Gene expression data were normalized to HSP90ab1 mRNA and are shown as fold change 
(mean +/- s.e.m.) relative to shControl cells. Experiments were performed in triplicate and Dunnett´s test following 
one-way ANOVA was performed. *: P<0.05. (F) Representative micrographs of immunocytochemistry assays 
showing vimentin (red, upper panels) and fibronectin (red, lower panels) in stably transfected shRspo3 (clone 4B) 
or shControl SCg6 cells; DAPI (blue) shows nuclei. (G) Representative images of wound healing assays 
performed with SCg6 cells, with a graph showing the quantitation of cell migration (n=4; *P<0.05 indicates 
statistically significant differences vs. shControl migration; Dunnett´s test following one-way ANOVA). (H) shRspo3 
and shControl cells were transiently transfected with Luciferase β-catenin reporter and β-galactosidase 
(normalizing transfection control) vectors. The reporter activity was measured 48 h after transfection. Error bars 
represent the s.d. (n=4). Student´s t-test, *P<0.05. 
Figure 5. Rspo3 down-regulation in SCg6 cells reduces tumor growth and metastasis in vivo. (A) Tumor 
growth of shRspo3 (clone: 4B) and shControl cells implanted subcutaneously. Tumors were measured with a 
caliper starting at 9 d after inoculation, when the tumors became detectable under the skin. Their volumes were 
calculated using the formula π/6 x a x b
2
, where a is the longest dimension of the tumor, and b is the width. (B) 
Representative image of intra-mammary shRspo3-4B and shControl tumors isolated from mice 20 days post-
injection (scale bar: 50 mm). (C) Tumor growth of shRspo3 (clone: 4B) and shControl cells implanted into #4 
mammary fat pad (day=0) BALB/c females. (D) Representative micrographs showing H&E (OM: 100x) and 
RSPO3, vimentin, Ki67 and cleaved-caspase 3 (CC3) IHC (OM: 400x) in shRspo3-4B and shControl tumors 
obtained after cell inoculation into cleared-fat pads. Arrowheads point to CC3 positive cells. Quantification of Ki67 
and CC3 positive cells is shown in lower graphs. Student´s t-test, *P<0.05. (E) Representative image and 
macrometastasis quantification of excised lungs 30 days after tail vein inoculation of shRspo3-4B and shControl 
cells. n=3. (F) Representative micrographs of H&E staining of lung tissue invaded by shRspo3-4B and shControl 
cells, 15 or 30 days after cell injection into the tail vein. *: mammary tumor cells; OM: 100x. (G) Metastasis 
quantification by lung metastasis area index, 30 days after cell inoculation; n=3. H&E: Hematoxylin and Eosin 
staining, OM: Original Magnification, IHC: immunohistochemistry. 
Figure 6. RSPO3 is expressed in human breast cancer and in the basal compartment of non-neoplastic 
breast tissue. IHC studies were carried out on several breast samples. (A) Lobular carcinoma in situ (LCIS) and 
stromal infiltrating cells (arrows) with moderate immunostaining and a small duct (arrowhead) with strong 
immunostaining for RSPO3. (B) Infiltrating cords (arrows) of a ductal not otherwise specified (NOS) carcinoma 
with moderate immunostaining for RSPO3. (C) Intense cytoplasmic immunostaining for RSPO3 in cells (arrows) of 
a ductal NOS carcinoma. (D) Rows of infiltrating cells from a lobular carcinoma, some with moderate (arrows) and 
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others with negative (arrowhead) immunostaining for RSPO3. Original magnification of A-D: 400x. (E-H) 
Representative micrographs showing intense RSPO3 immunostaining in basal and myoepithelial cells of lobules 
and ducts from human hyperplastic breast sections; scale bar of left panels: 50 µm; scale bars of right panels: 100 
µm. Original magnification of E-H: 400x. (I-N) Representative tissue microarray micrographs of ductal invasive 
breast carcinoma samples showing infiltrating cords with cytoplasmic negative (I-J), low/moderate (K-L) or strong 
(M-N) RSPO3 immunostaining. In (J) tumor tissue is surrounded by positive lymphocytes and fibroblasts. In (M) 
some cells display a perinuclear reinforcement of RSPO3 expression. Original magnification of I-M: 400x. 
Percentages of cases with negative, low/moderate and strong RSPO3 immunostaining are indicated for each of 
these categories. 
Figure 7. Basal-like breast tumors show high expression of RSPO3. (A) RSPO3 expression levels according 
to ER, PR, and Her2 biomarker expression using in silico data mining of the TCGA cBioportal METABRIC 
database (1985 samples). ER
-
PR
-
Her2
-
 vs: ER
-
PR
-
Her2
+
, ER
-
PR
+
Her2
-
 or ER
-
PR
+
Her2
+
 resulted not significant by 
Pairwise comparisons using Tukey and Kramer test. (B) Comparative box plot analysis of RSPO3 mRNA 
expression profiles according to intrinsic subtypes (luminal A, luminal B, Her2, and basal-like) among primary 
breast carcinomas, by Pairwise comparisons using Tukey and Kramer test and the same TCGA’s dataset as in A. 
Correlation analysis among normal and breast cancer samples was done using R/Bioconductor software. (C) 
Comparative box plot analysis of RSPO3 mRNA expression, according to intrinsic breast cancer subtypes, 
separating claudin-low subtype from basal-like category using the same TCGA’s dataset as in A. (D) Box plot 
expression analysis of RSPO3 with respect to expression level of CDH1 (E-cadherin), VIM (vimentin), SNAI2 
(Slug), and TWIST, as EMT markers, using the same TCGA’s dataset as in A. Kruskal-Wallis chi-squared was 
used as statistic test. (E) Box plot of RSPO3 mRNA expression in association with stromal and immune scores 
using the ESTIMATE method in the TCGA-Breast cancer RNA-Seq dataset (1097 primary breast carcinomas 
samples) obtained from UCSC Xena Browser (https://xenabrowser.net). RSPO3 mRNA expression was classified 
in high or low levels based on StepMiner one-step algorithm. (F) RSPO3 mRNA levels in association with 
negative/low or moderate/high LGR4-6 expression levels among the TCGA-Breast cancer RNA-Seq dataset as in 
E. (G) Correlation analysis of RSPO3 expression with mRNA levels of its putative receptors, LGR4-6, and a 
member of the transcription factor family of RUNX genes, RUNX3, in human breast samples using the TCGA-
Breast cancer RNA-Seq dataset as in E. (H) LGR4-6 and RUNX3 expression levels among the intrinsic breast 
cancer subtypes based on gene expression profiling, using the same the TCGA-Breast cancer RNA-Seq dataset 
as in E. 
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